David Turkaly
Stock Analyst at JMP Securities
(2.11)
# 2,939
Out of 4,983 analysts
139
Total ratings
37.8%
Success rate
-4.24%
Average return
Main Sectors:
Stocks Rated by David Turkaly
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KIDS OrthoPediatrics | Maintains: Market Outperform | $50 → $35 | $19.59 | +78.66% | 11 | Aug 8, 2025 | |
| LNTH Lantheus Holdings | Maintains: Market Outperform | $112 → $73 | $51.98 | +40.44% | 9 | Aug 7, 2025 | |
| OFIX Orthofix Medical | Reiterates: Market Perform | n/a | $14.84 | - | 2 | Jun 6, 2025 | |
| GMED Globus Medical | Reiterates: Market Perform | n/a | $57.84 | - | 3 | May 27, 2025 | |
| HAE Haemonetics | Reiterates: Market Outperform | $100 | $51.02 | +96.00% | 12 | May 20, 2025 | |
| STE STERIS | Maintains: Market Outperform | $265 → $280 | $247.99 | +12.91% | 18 | May 16, 2025 | |
| IART Integra LifeSciences Holdings | Maintains: Market Outperform | $35 → $25 | $14.83 | +68.58% | 15 | May 9, 2025 | |
| ENOV Enovis | Maintains: Market Outperform | $62 → $55 | $33.32 | +65.07% | 2 | May 9, 2025 | |
| ZBH Zimmer Biomet Holdings | Maintains: Market Outperform | $140 → $125 | $99.12 | +26.11% | 14 | May 7, 2025 | |
| CRWD CrowdStrike Holdings | Maintains: Market Outperform | $400 → $500 | $444.98 | +12.36% | 1 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $376.62 | - | 3 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $125.82 | - | 15 | Apr 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $12 → $7 | $1.58 | +343.04% | 6 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $26 | $16.73 | +55.41% | 7 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $32 | $15.10 | +111.92% | 7 | Feb 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $16 | $7.74 | +106.72% | 1 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $2.13 | - | 5 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $7 → $3 | $2.77 | +8.30% | 7 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $5 | $8.34 | -40.05% | 1 | Oct 6, 2017 |
OrthoPediatrics
Aug 8, 2025
Maintains: Market Outperform
Price Target: $50 → $35
Current: $19.59
Upside: +78.66%
Lantheus Holdings
Aug 7, 2025
Maintains: Market Outperform
Price Target: $112 → $73
Current: $51.98
Upside: +40.44%
Orthofix Medical
Jun 6, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $14.84
Upside: -
Globus Medical
May 27, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $57.84
Upside: -
Haemonetics
May 20, 2025
Reiterates: Market Outperform
Price Target: $100
Current: $51.02
Upside: +96.00%
STERIS
May 16, 2025
Maintains: Market Outperform
Price Target: $265 → $280
Current: $247.99
Upside: +12.91%
Integra LifeSciences Holdings
May 9, 2025
Maintains: Market Outperform
Price Target: $35 → $25
Current: $14.83
Upside: +68.58%
Enovis
May 9, 2025
Maintains: Market Outperform
Price Target: $62 → $55
Current: $33.32
Upside: +65.07%
Zimmer Biomet Holdings
May 7, 2025
Maintains: Market Outperform
Price Target: $140 → $125
Current: $99.12
Upside: +26.11%
CrowdStrike Holdings
May 5, 2025
Maintains: Market Outperform
Price Target: $400 → $500
Current: $444.98
Upside: +12.36%
May 5, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $376.62
Upside: -
Apr 2, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $125.82
Upside: -
Mar 21, 2025
Maintains: Market Outperform
Price Target: $12 → $7
Current: $1.58
Upside: +343.04%
Mar 5, 2025
Reiterates: Market Outperform
Price Target: $26
Current: $16.73
Upside: +55.41%
Feb 25, 2025
Reiterates: Market Outperform
Price Target: $32
Current: $15.10
Upside: +111.92%
Jan 29, 2025
Reiterates: Market Outperform
Price Target: $16
Current: $7.74
Upside: +106.72%
Sep 16, 2024
Reiterates: Market Perform
Price Target: n/a
Current: $2.13
Upside: -
Aug 14, 2024
Maintains: Market Outperform
Price Target: $7 → $3
Current: $2.77
Upside: +8.30%
Oct 6, 2017
Initiates: Outperform
Price Target: $5
Current: $8.34
Upside: -40.05%